News | July 10, 2022
Sirio Pharma announces agreement to acquire best formulations
The combined company will be able to better serve both our global and regional customers with local production
The combined company will be able to better serve both our global and regional customers with local production
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Site Enhances New Modality CRDMO Platform Capacity for Customers
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Govt committed to supporting pharma companies with industry-friendly policies
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
Subscribe To Our Newsletter & Stay Updated
